Varex Imaging Corp (VREX) Stock Analysis and Metrics

Varex Imaging

NASDAQ: VREX

$10.94 ▲ +0.22 (+2.01%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap450.24 Mn

P/E-5.46

P/S0.53

Div. Yield0.00

ROIC (Qtr)-0.02

Total Debt (Qtr)366.20 Mn

Revenue Growth (1y) (Qtr)1.46

Add ratio to table…

About

Varex Imaging Corporation designs manufactures and sells X ray imaging components and systems for medical security and industrial applications. The company produces X ray tubes flat panel and photon counting detectors high voltage connectors image processing software workstations and related accessories. Its products are incorporated into original equipment manufacturer systems that serve computed tomography mammography cardiac surgery dental fluoroscopy and other diagnostic radiology modalities. In addition Varex supplies X ray based solutions for cargo screening airport baggage inspection nondestructive testing irradiation and industrial quality control. The firm operates engineering manufacturing and service sites across North America Europe and Asia employing approximately two thousand four hundred full time workers. It invests heavily in research and development to maintain technological leadership and to extend product life cycles. The firm also maintains a global supply chain that sources raw materials from multiple countries to mitigate risks associated with geopolitical tensions and commodity price fluctuations. Varex emphasizes quality management and holds certifications such as ISO 9001 for its security and inspection products and ISO 13485 for its medical devices.

Varex generates revenue primarily through the sale of its X ray imaging components to original equipment manufacturers that integrate the parts into their own systems. The company also sells directly to independent service companies distributors and end users needing replacement parts or upgrades. Service contracts that provide maintenance repair and technical support contribute a steady stream of income. Licensing of proprietary image processing and detection software adds another revenue source especially for industrial customers seeking packaged sub assembly solutions. Revenue is recognized when products are shipped or when services are rendered based on the final destination of the goods in the Americas EMEA and APAC regions. Service revenue benefits from long term contracts that cover preventive maintenance emergency repairs and performance upgrades for installed equipment. Licensing arrangements often include royalty payments tied to the volume of systems that incorporate the software thereby aligning income with customer usage.

The company operates through the following segments: Medical and Industrial.

• The Medical segment designs manufactures sells and services X ray tubes flat panel and photon counting detectors high voltage connectors image processing software workstations 3D reconstruction software computer aided diagnostic software automatic exposure control devices generators and coolers for use in computed tomography mammography oncology cardiac surgery dental fluoroscopy and other diagnostic radiology applications. These components are sold mainly to original equipment manufacturers that incorporate them into their imaging systems and also to independent service firms distributors and end users for replacement and support. A large portion of Medical revenue comes from the installed base of products requiring periodic replacement of tubes detectors and related hardware. The installed base of Medical components creates recurring demand for replacement tubes detectors and associated service work which contributes significantly to the segment's top line.

• The Industrial segment designs develops manufactures sells and services X ray imaging products for security cargo screening airport baggage inspection nondestructive testing irradiation and industrial quality inspection applications. Its offerings include Linatron® X ray linear accelerators non intrusive cargo inspection systems X ray tubes flat panel and photon counting detectors computed radiography scanners high voltage connectors coolers and proprietary image processing and detection software. The segment also manufactures and sells stand alone X ray based systems for industrial use and benefits from long term service agreements on Linatron products. Industrial gross margins tend to be higher than Medical margins due to economies of scale and favorable pricing dynamics. Industrial gross margins benefit from lower price sensitivity in security and nondestructive testing markets and from the ability to offer bundled solutions that combine hardware software and service.

Varex Imaging Corporation holds a leading position as one of the largest independent suppliers of X ray imaging components worldwide competing with in house production of major original equipment manufacturers and with specialized component makers. In the Medical segment its main rivals include the internal X ray tube operations of Canon Medical Systems General Electric and Siemens Healthineers as well as external detector suppliers such as Trixell Vieworks Hamamatsu iRay and CareRay. In the Industrial segment the company faces competition from firms like iRay Teledyne Comet Nuctech and various providers of cargo scanning and nondestructive testing equipment. Varex sustains its advantage through a broad product portfolio strong research and development capabilities long term customer relationships and the ability to leverage technology synergies between its Medical and Industrial businesses. Its scale enables cost reductions by spreading fixed costs over high volume production while its focus on innovation yields improvements in tube life detector performance and software functionality that customers value. These factors help Varex maintain market share and pricing power in a highly competitive environment. The company allocates a substantial portion of its operating budget to research and development resulting in a steady flow of patented innovations that protect its technological edge. Varex also leverages its global manufacturing footprint to shift production to regions with favorable cost structures while maintaining close proximity to key customer bases.

The company serves primarily large original equipment manufacturers that integrate its X ray imaging components into their own diagnostic security and industrial systems. Among its most significant customers are Canon Medical Systems Corporation United Imaging Healthcare General Electric Company Siemens Healthineers AG and Rapiscan Systems Inc which together accounted for about forty percent of total revenue in the most recent fiscal year. The ten largest customers as a group represent roughly half of Varex sales demonstrating a concentrated but loyal buyer base. In addition to OEMs Varex sells to independent service firms distributors and end users seeking replacement parts upgrades and technical support. This diverse customer mix provides stability and opportunities for recurring revenue from the installed base of its products. Many of these OEM relationships have endured for decades reflecting deep integration of Varex components into customer product roadmaps and long term supply agreements. The company also pursues strategic partnerships with system integrators to expand its reach into emerging markets such as Southeast Asia and Latin America.

Investment Thesis

▲ Bull case

Varex Imaging is positioned to benefit significantly from the accelerating adoption of photon counting technology across multiple imaging modalities beyond CT, with eight active OEM engagements in non-CT applications such as CBCT, DR, and breast imaging. Management emphasized that full-body photon counting CT remains the company's largest long-term market opportunity, and while two CT OEM customers are making steady progress toward commercialization aligned with 2029 goals, the broadening engagement across modalities indicates a diversified pipeline that could drive earlier-than-expected recurring revenue streams. This expansion reduces reliance on a single modality and positions VREX to capture value as OEMs seek differentiation through advanced imaging capabilities, particularly as AI integration increases demand for high-quality, preprocessed image data directly at the detector level. The company's tube and smart detector technologies enable preprocessing that supports Agentic AI applications, addressing radiologist shortages in emerging markets—a structural tailwind not fully reflected in current guidance.
The India manufacturing ramp, while currently a headwind to gross margins and operating expenses due to low utilization, represents a structural cost advantage in the making. Detector factory utilization is expected to reach 60%-70% by year-end, with gradual approval-driven ramp, and once achieved, will create meaningful margin tailwinds through lower labor and production costs. Management explicitly framed the current impact as a temporary headwind that will reverse into a tailwind upon crossing utilization thresholds, and the tube factory's ongoing facilitization phase suggests additional capacity is being built for future scaling. This dual-track ramp in India not only de-risks supply chain concentration but also supports long-term gross margin expansion independent of near-term revenue growth, offering a leveraged upside to profitability as utilization inflects upward.
Cargo security systems are demonstrating sustained momentum with multiple new deals booked across various countries, including mobile inspection systems and car scanners, signaling broadening adoption beyond traditional fixed installations. Management expressed strong visibility into the pipeline, noting well-distributed bookings from new prospects, geographies, and products, and highlighted that installations are progressing as anticipated. This business, while lumpy and tender-driven, is becoming an increasingly significant driver of Industrial segment growth and margin expansion, with Industrial Services already contributing to gross margin expansion by offsetting inflationary cost increases. The reacceleration in cargo security orders, combined with ongoing implementation driving temporary inventory buildup, points to a deferred revenue recognition tailwind that could bolster second-half performance as acceptance procedures conclude and revenue converts from backlog.

Varex Imaging is positioned to benefit significantly from the accelerating adoption of photon counting technology across multiple imaging modalities beyond CT, with eight active OEM engagements in non-CT applications such as CBCT, DR, and breast imaging. Management emphasized that full-body photon counting CT remains the company's largest long-term market opportunity, and while two CT OEM customers are making steady progress toward commercialization aligned with 2029 goals, the broadening engagement across modalities indicates a diversified pipeline that could drive earlier-than-expected recurring revenue streams. This expansion reduces reliance on a single modality and positions VREX to capture value as OEMs seek differentiation through advanced imaging capabilities, particularly as AI integration increases demand for high-quality, preprocessed image data directly at the detector level. The company's tube and smart detector technologies enable preprocessing that supports Agentic AI applications, addressing radiologist shortages in emerging markets—a structural tailwind not fully reflected in current guidance.
The India manufacturing ramp, while currently a headwind to gross margins and operating expenses due to low utilization, represents a structural cost advantage in the making. Detector factory utilization is expected to reach 60%-70% by year-end, with gradual approval-driven ramp, and once achieved, will create meaningful margin tailwinds through lower labor and production costs. Management explicitly framed the current impact as a temporary headwind that will reverse into a tailwind upon crossing utilization thresholds, and the tube factory's ongoing facilitization phase suggests additional capacity is being built for future scaling. This dual-track ramp in India not only de-risks supply chain concentration but also supports long-term gross margin expansion independent of near-term revenue growth, offering a leveraged upside to profitability as utilization inflects upward.
Cargo security systems are demonstrating sustained momentum with multiple new deals booked across various countries, including mobile inspection systems and car scanners, signaling broadening adoption beyond traditional fixed installations. Management expressed strong visibility into the pipeline, noting well-distributed bookings from new prospects, geographies, and products, and highlighted that installations are progressing as anticipated. This business, while lumpy and tender-driven, is becoming an increasingly significant driver of Industrial segment growth and margin expansion, with Industrial Services already contributing to gross margin expansion by offsetting inflationary cost increases. The reacceleration in cargo security orders, combined with ongoing implementation driving temporary inventory buildup, points to a deferred revenue recognition tailwind that could bolster second-half performance as acceptance procedures conclude and revenue converts from backlog.

▼ Bear case

Varex Imaging faces persistent structural headwinds in EMEA, where revenue declined 16% year-over-year, driven by the lapping of a large linear accelerator order from a European-based customer in the prior year. Management acknowledged that industrial revenue for linear accelerators was exceptionally strong in fiscal 2025 due to this single customer's large order, and the current year-over-year comparison reflects a natural trough in a lumpy, project-based business. While security inspection systems are gaining traction in EMEA, they have not yet offset the decline from the lapsed linear accelerator business, creating a revenue gap that management did not adequately address when discussing overall Industrial segment growth. This reliance on episodic large orders introduces volatility that is not fully mitigated by diversification efforts, and the segment's growth remains dependent on winning infrequent, high-value tenders rather than consistent recurring demand.
Inventory buildup remains a material and underappreciated risk, with days of inventory increasing to 220—up six days sequentially—and a $19 million quarter-over-quarter rise to $347 million. While management attributed this to temporary factors including cargo system implementations and India ramp-related raw material transfers, the scale of the increase suggests deeper inefficiencies in demand forecasting or supply chain alignment. The company's target to reduce inventory by $20 million–$25 million in coming quarters is ambitious given the concurrent ramp of two new manufacturing facilities in India, which requires sustained raw material and work-in-process investment. Failure to achieve this reduction would tie up working capital, increase storage and obsolescence risks, and constrain free cash flow generation, particularly as net debt leverage stands at 2.2x trailing twelve-month adjusted EBITDA, leaving limited buffer for further working capital deterioration.
The noncash mark-to-market charge of $1.8 million related to the Micro-X equity investment, which management confirmed is not adjusted out of non-GAAP metrics, continues to distort profitability metrics and may recur if Micro-X's share price remains volatile. This charge directly impacted GAAP net loss ($8 million) and GAAP EPS ($0.19 loss), creating a divergence between GAAP and non-GAAP performance that could erode investor trust if perceived as recurring or inadequately disclosed. More critically, the decision not to adjust this charge suggests a reluctance to isolate core operational performance, raising concerns about transparency in how management presents earnings quality. In an environment where investors scrutinize adjusted metrics for sustainability, this policy could lead to multiple compression if the market begins to question the reliability of VREX's reported non-GAAP earnings as a proxy for true operational earnings power.

Varex Imaging faces persistent structural headwinds in EMEA, where revenue declined 16% year-over-year, driven by the lapping of a large linear accelerator order from a European-based customer in the prior year. Management acknowledged that industrial revenue for linear accelerators was exceptionally strong in fiscal 2025 due to this single customer's large order, and the current year-over-year comparison reflects a natural trough in a lumpy, project-based business. While security inspection systems are gaining traction in EMEA, they have not yet offset the decline from the lapsed linear accelerator business, creating a revenue gap that management did not adequately address when discussing overall Industrial segment growth. This reliance on episodic large orders introduces volatility that is not fully mitigated by diversification efforts, and the segment's growth remains dependent on winning infrequent, high-value tenders rather than consistent recurring demand.
Inventory buildup remains a material and underappreciated risk, with days of inventory increasing to 220—up six days sequentially—and a $19 million quarter-over-quarter rise to $347 million. While management attributed this to temporary factors including cargo system implementations and India ramp-related raw material transfers, the scale of the increase suggests deeper inefficiencies in demand forecasting or supply chain alignment. The company's target to reduce inventory by $20 million–$25 million in coming quarters is ambitious given the concurrent ramp of two new manufacturing facilities in India, which requires sustained raw material and work-in-process investment. Failure to achieve this reduction would tie up working capital, increase storage and obsolescence risks, and constrain free cash flow generation, particularly as net debt leverage stands at 2.2x trailing twelve-month adjusted EBITDA, leaving limited buffer for further working capital deterioration.
The noncash mark-to-market charge of $1.8 million related to the Micro-X equity investment, which management confirmed is not adjusted out of non-GAAP metrics, continues to distort profitability metrics and may recur if Micro-X's share price remains volatile. This charge directly impacted GAAP net loss ($8 million) and GAAP EPS ($0.19 loss), creating a divergence between GAAP and non-GAAP performance that could erode investor trust if perceived as recurring or inadequately disclosed. More critically, the decision not to adjust this charge suggests a reluctance to isolate core operational performance, raising concerns about transparency in how management presents earnings quality. In an environment where investors scrutinize adjusted metrics for sustainability, this policy could lead to multiple compression if the market begins to question the reliability of VREX's reported non-GAAP earnings as a proxy for true operational earnings power.

Segments Breakdown of Revenue (2025)

Peer Comparison

Companies in the Medical Devices

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ABT	Abbott Laboratories	201.40 Bn	27.98	4.46	34.05 Bn
2	SYK	Stryker Corp	122.29 Bn	36.60	4.84	14.72 Bn
3	MDT	Medtronic plc	105.01 Bn	21.73	2.89	27.96 Bn
4	BSX	Boston Scientific Corp	64.81 Bn	18.16	3.14	11.03 Bn
5	EW	Edwards Lifesciences Corp	55.28 Bn	2,354.76	8.77	0.60 Bn
6	DXCM	Dexcom Inc	29.06 Bn	29.17	6.03	-
7	PHG	Koninklijke Philips Nv	29.02 Bn	22.06	1.42	9.48 Bn
8	GEHC	GE HealthCare Technologies Inc.	28.27 Bn	14.30	1.35	10.14 Bn

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password